Editas Medicine– tag –
-
Beam Therapeutics Pursues Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Citing Positive Phase 1/2 Clinical Data
Simply Wall St USA Overview Beam Therapeutics announced updated Phase 1/2 clinical trial data for BEAM-302, its treatment for Alpha-1 Antitrypsin Deficiency (AATD), showing an acceptable safety profile and promising biomarker data indica... -
Rewriting Sickle Cell Disease: The Promise of In Vivo Gene Editing and the Global Equity Challenge
Current Opinion in Hematology USA Overview The quest to cure sickle cell disease (SCD) hinges on establishing durable, healthy hematopoiesis without significant toxicity. While cutting-edge in vivo and prenatal hematopoietic stem cell (H... -
CRISPR Therapeutics Reports Deep, Durable Lipid Lowering from In Vivo Gene Editor CTX310 in Phase 1a Trial
MarketScreener (CRISPR Therapeutics) Switzerland Overview CRISPR Therapeutics AG announced compelling one-year durability data from its Phase 1a clinical trial of CTX310, an in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3. A s... -
ESC Congress 2026 Reveals Breakthrough Gene Therapies for Cardiovascular Disease: AAV8 Reduces LDL-C by 80-90%, siRNA Kylo-11 Achieves 97% Lp(a) Reduction
HCPLive (YouTube) USA Overview Groundbreaking data on multiple gene and molecular therapies for cardiovascular disease were presented at ESC Congress 2026. An AAV8-mediated gene therapy for homozygous familial hypercholesterolemia (HoFH)... -
CRISPR Frontiers 2026: Innovations in DSB-Independent Editing and Delivery Systems Boost Genome Editing Precision and Stability
Addgene Blog USA Overview The 'Genome Engineering: CRISPR Frontiers 2026' conference reported significant evolution in CRISPR technology towards precise, double-strand break (DSB)-independent editing. Researchers are focusing on enhancin... -
Next-Generation CRISPR Tools Revolutionize Precise Gene Editing, Bypassing Double-Strand Breaks for Enhanced Therapeutic Safety and Consistency
News-Medical.net USA Overview Next-generation CRISPR technologies are fundamentally transforming cell and gene therapy by enabling precise gene editing without relying on double-strand DNA breaks (DSBs). Advances in base editing, prime e... -
Editas Medicine Stock Soars 14.4% on Q2 Revenue Beat, Investor Focus on Gene-Editing Pipeline Intensifies
MarketBeat USA Overview Editas Medicine reported a Q2 2026 revenue of $11.89 million, significantly surpassing analyst estimates of $2.85 million, alongside an adjusted EPS loss of $0.15, better than the projected $0.27 loss, leading to ... -
Children’s Hospital Los Angeles Joins Multi-Center Trial for In Vivo CRISPR Gene Editing Therapy for Sickle Cell Disease
Children's Hospital Los Angeles (CHLA) Facebook USA Overview Children's Hospital Los Angeles (CHLA) has announced its participation in a multi-center clinical trial evaluating a novel CRISPR-based, direct gene editing therapy for sickle ... -
CRISPR and the Dawn of Germline Editing: Curing Hereditary Disease at the Source
Liv Hospital Turkey Overview Germline genome editing, often referred to as 'baby gene editing,' leverages advanced CRISPR technology to offer a potentially curative approach for monogenic diseases at the embryonic stage. While CRISPR's e... -
CRISPR Gene Editing Achieves Clinical Breakthroughs in Sickle Cell Disease Treatment
Liv Hospital Turkey Overview Clinical trials employing CRISPR gene-editing technology for sickle cell disease are reporting highly promising results, significantly reducing severe vaso-occlusive crises and transfusion dependency. Utilizi...
